Læknablaðið - feb. 2019, Blaðsíða 32

84 LÆKNAblaðið 2019/105
R A N N S Ó K N
Gestur Þorgeirsson1,2
Birna Björg Másdóttir1
Þórarinn Guðnason1,2
María Heimisdóttir1,2
Background: Marked changes in the epidemiology of acute
coronary syndromes (ACS) have been observed over the last few
decades in the Western Hemisphere. Incidence rates of ACS in
Iceland 2003-2012 are presented.
Methods: All patients with unstable angina (UA), non ST-elevation
myocardial infarction (NSTEMI) and ST-elevation myocardial infarc-
tion (STEMI) admitted to Landspitali were included in the study.
Data were obtained from hospital records and changes during the
period were examined.
Results: The total number of ACS cases was 7,502. STEMI
incidence was reduced from 98/100,000 inhabitants in 2003 to 63 in
2012, a reduction of nearly 36%. Age standardized incidence rates
of STEMI declined annually by 5.5% in men and 5.3% in women (p
<0.05). Incidence of NSTEMI increased from 54 /100,000 inhabitants
in 2003 to 93 in 2012. UA patients were 56/100,000 inhabitants in
2003, 115 in 2008 and 50 in 2012. No significant annual change in
age-standardized incidence rates of NSTEMI and UA was obser-
ved. About 35% of patients with NSTEMI and 30% with STEMI and
UA were female. The mean age of NSTEMI patients was 72 years,
five years higher than patients with STEMI and UA. About 30% of
pat ients were living outside of the capital region.
Conclusions: 2003-2012 there was a significant 5% annu-
al decrease in the number of STEMI cases and a tendency to
increasing incidence of NSTEMI which by the end of the research
period was the most common of the syndromes. An unusual
development in the incidence of UA was observed. Possible effect
of psychological stress in the society should be considered.
Acute coronary syndromes in Landspítali 2003-2012
ENGLISH SUMMARY
1Department of Internal Medicine, Division of Cardiology, Landspitali - The National University Hospital of Iceland, 2Faculty of Medicine, University of Iceland, 3Department of
Finance and Information, Landspitali - The National University Hospital of Iceland.
Key words: STEMI, NSTEMI, unstable angina, incidence, troponin.
Correspondence: Gestur Þorgeirsson, gesturth@landspitali.is
Lyngonia — áhrifarík meðferð án sýklalyfja
Lyngonia er notað við vægum endurteknum
þvagfærasýkingum hjá konum og verkar
m.a. á brunatilfinningu og aukin þvaglát.

Lyngonia er fyrsta skráða jurtalyfið á
Íslandi og er unnið úr sortulyngslaufi.
Fæst án lyfseðils í flestum apótekum.
Sjá meira á florealis.is
Notkun Fullorðnar og aldraðar konur: 2 töflur 2–4 sinnum á dag.
Ekki nota Lyngonia ef þú ert með einhverja truflun á nýrnastarfsemi.
Hvorki ætlað þunguðum konum né konum með barn á brjósti, körlum
eða börnum og unglingum yngri en 18 ára. Notið ekki lengur en í 1 viku.

Ef einkenni eru viðvarandi í meira en 4 daga, eða versna við notkun Lyngonia,
skal hafa samband við lækni. Lesið vandlega upplýsingar á umbúðum og
fylgiseðli fyrir notkun lyfsins. Leitið til læknis eða lyfjafræðings sé þörf á
frekari upplýsingum um áhættu og aukaverkanir.

Sjá nánari upplýsingar um lyfið á www.serlyfjaskra.is.